Development of 3 β ,4 α ‐dihydroxy‐5 α ‐androstan‐17‐one standard solution for doping analyses
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Miho Kuroe und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Advanced Industrial Science and Technology (AIST), National Metrology Institute of Japan (NMIJ), Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Doping in Sports, Substance Abuse Detection, Androstanols, Anabolic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Doping analyses are essential for sporting events because some athletes might use prohibited substances to win games. To obtain reliable results from doping analyses, it is important to use both reliable standard solutions and validated analytical methods at accredited laboratories. Among the focused compounds related to prohibited substances listed by the World Anti‐Doping Agency, we developed a certified reference material (CRM) for 3 β ,4 α ‐dihydroxy‐5 α ‐androstan‐17‐one (DHAS), a metabolite of formestane that is used to conceal prohibited anabolic steroids, in methanol solution (NMIJ CRM 6212‐a). To develop a CRM traceable to the International System of Units (SI), we newly applied different analytical methods with an SI‐traceable internal standard for quantitative NMR (qNMR) instead of mass balance approach because this CRM solution was required to develop rapidly using a limited amount of high‐purity DHAS. One method was gravimetric blending using the purity of DHAS powder evaluated by both qNMR and a combination of qNMR and high‐performance liquid chromatography (HPLC), and the other was direct quantification of the DHAS mass fraction in the candidate solution CRM by both qNMR and qNMR/HPLC. Because the values obtained by gravimetric blending and direct quantification of the mass fraction were comparable, the arithmetic mean was applied to obtain the certified value. Considering homogeneity and stability according to ISO Guide 35: 2017, the certified values with expanded uncertainties (coverage factor k = 2, approximate 95% confidence interval) were (135.2 ± 9.5) μg/g for the mass fraction and (107.0 ± 7.5) μg/ml for the mass concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Advanced Industrial Science and Technology (AIST), National Metrology Institute of Japan (NMIJ), Tsukuba, Ibaraki, Japan.
ORCID-Profile: Miho Kuroe, Taichi Yamazaki, Naoki Saito, Yoshitaka Shimizu, Toshihide Ihara, Masahiko Numata, Nobuyasu Itoh
Zitieren
APA
Kuroe, M., Yamazaki, T., Saito, N., Shimizu, Y., Ihara, T., Numata, M., & Itoh, N. (2025). Development of 3 β ,4 α ‐dihydroxy‐5 α ‐androstan‐17‐one standard solution for doping analyses. Drug Testing and Analysis. https://doi.org/10.1002/dta.3686
Vancouver
Kuroe M, Yamazaki T, Saito N, Shimizu Y, Ihara T, Numata M, et al. Development of 3 β ,4 α ‐dihydroxy‐5 α ‐androstan‐17‐one standard solution for doping analyses. Drug Testing and Analysis. 2025. doi:10.1002/dta.3686
BibTeX
@article{Kuroe2025,
author = {Kuroe, Miho and Yamazaki, Taichi and Saito, Naoki and Shimizu, Yoshitaka and Ihara, Toshihide and Numata, Masahiko and Itoh, Nobuyasu},
title = {Development of 3 β ,4 α ‐dihydroxy‐5 α ‐androstan‐17‐one standard solution for doping analyses},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3686}
}
EUVIMED